2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

[1]  P. Wells,et al.  Apixaban to Prevent Venous Thromboembolism in Patients with Cancer , 2019, The New England journal of medicine.

[2]  Cassini Investigators.  Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. , 2019 .

[3]  G. Lyman,et al.  Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. , 2019, Thrombosis research.

[4]  A. Altman,et al.  Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery. , 2019, American journal of surgery.

[5]  Paolo Prandoni,et al.  Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. , 2018, European heart journal.

[6]  C. Loprinzi,et al.  Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial , 2018, Blood.

[7]  Mary R. Kwaan,et al.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. , 2018, The Cochrane database of systematic reviews.

[8]  H. Seo,et al.  Venous Thromboembolism Incidence and Prophylaxis Use After Gastrectomy Among Korean Patients With Gastric Adenocarcinoma: The PROTECTOR Randomized Clinical Trial , 2018, JAMA surgery.

[9]  G. Chatellier,et al.  Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial , 2018, European Respiratory Journal.

[10]  F. Goldwasser,et al.  Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. , 2018, Critical reviews in oncology/hematology.

[11]  Georg Heinze,et al.  A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. , 2018, The Lancet. Haematology.

[12]  A. Khorana,et al.  Management of anticoagulation for cancer‐associated thrombosis in patients with thrombocytopenia: A systematic review , 2018, Research and practice in thrombosis and haemostasis.

[13]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. , 2018, The Cochrane database of systematic reviews.

[14]  Lara A. Kahale,et al.  Anticoagulation for people with cancer and central venous catheters. , 2018, The Cochrane database of systematic reviews.

[15]  S. Yeung,et al.  Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta‐analysis of randomized controlled trials (RCTs) , 2018, Asia-Pacific journal of clinical oncology.

[16]  Jae Seung Lee,et al.  Effect of post-filter anticoagulation on mortality in patients with cancer-associated pulmonary embolism , 2018, International Journal of Clinical Oncology.

[17]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Khorana,et al.  Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study , 2018, Thrombosis and Haemostasis.

[19]  C. Font,et al.  Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer , 2018, British Journal of Cancer.

[20]  Zhouqiao Wu,et al.  Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer. , 2018, Journal of thoracic disease.

[21]  D. Wagner,et al.  Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients , 2018, Journal of thrombosis and haemostasis : JTH.

[22]  Lara A. Kahale,et al.  Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. , 2018, The Cochrane database of systematic reviews.

[23]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[24]  P. Stein,et al.  Inferior Vena Cava Filters in Patients with Acute Pulmonary Embolism and Cancer. , 2017, The American journal of medicine.

[25]  L. Ek,et al.  Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. Konety,et al.  Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. , 2017, Urologic oncology.

[27]  Yuan Tian,et al.  Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis , 2015, Oncotarget.

[28]  Lara A. Kahale,et al.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2021, The Cochrane database of systematic reviews.

[29]  J. Durack,et al.  Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism , 2017, Journal of Thrombosis and Thrombolysis.

[30]  Lara A. Kahale,et al.  Parenteral anticoagulation in ambulatory patients with cancer. , 2017, The Cochrane database of systematic reviews.

[31]  P. Bossuyt,et al.  Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study , 2017, Haematologica.

[32]  Bradford J. Kim,et al.  Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective , 2017, Journal of thrombosis and haemostasis : JTH.

[33]  A. Mansfield,et al.  Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. , 2017, Thrombosis research.

[34]  Xiaojiong Du,et al.  Perioperative Pharmacological Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis , 2017, Annals of surgery.

[35]  H. Abdel-Razeq,et al.  A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS–Cancer‐Associated Thrombosis Study , 2017, The oncologist.

[36]  R. White,et al.  Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study. , 2017, Thrombosis research.

[37]  E. Matano,et al.  Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. , 2017, The oncologist.

[38]  D. Lötsch,et al.  Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. , 2017, Blood.

[39]  D. Rubens,et al.  Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. , 2017, Thrombosis research.

[40]  L. Robertson,et al.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. , 2017, The Cochrane database of systematic reviews.

[41]  N. Smith,et al.  Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin , 2017, The Journal of urology.

[42]  A. Iorio,et al.  Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours , 2015, Thrombosis and Haemostasis.

[43]  A. Cohen,et al.  Cancer-associated venous thromboembolism: Burden, mechanisms, and management , 2016, Thrombosis and Haemostasis.

[44]  T. Hermanns,et al.  Risk stratification for venous thromboembolism in patients with testicular germ cell tumors , 2016, PloS one.

[45]  H. García‐Perdomo,et al.  Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis , 2017, Journal of Thrombosis and Thrombolysis.

[46]  R. Yusen,et al.  Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. , 2016, JACC. Cardiovascular interventions.

[47]  J. Armitage,et al.  Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia , 2016, American journal of hematology.

[48]  Yifan Dai,et al.  Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. , 2016, Journal of cancer research and therapeutics.

[49]  H. García‐Perdomo,et al.  A meta‐analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: comment , 2016, Journal of thrombosis and haemostasis : JTH.

[50]  J. Zwicker,et al.  A meta‐analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: reply , 2016, Journal of thrombosis and haemostasis : JTH.

[51]  J. Douketis,et al.  International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. , 2016, The Lancet. Oncology.

[52]  D. Kondziolka,et al.  Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.

[53]  Timothy R. Smith,et al.  Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis , 2016, Journal of Neuro-Oncology.

[54]  A. Mansfield,et al.  Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer , 2016, Journal of thrombosis and haemostasis : JTH.

[55]  F. Jen,et al.  A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment , 2016, Journal of Thrombosis and Thrombolysis.

[56]  J. Coresh,et al.  The Impact of Cancer on the Clinical Outcome of Patients After Inferior Vena Cava Filter Placement: A Retrospective Cohort Study , 2016, American journal of clinical oncology.

[57]  R. White,et al.  Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes. , 2016, Thrombosis research.

[58]  T. H. Oo,et al.  Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[59]  M. Ovanesov,et al.  Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma. , 2016, Thrombosis research.

[60]  Agnes Y. Y. Lee,et al.  Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis , 2015, Annals of Surgical Oncology.

[61]  L. Landrum,et al.  Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate , 2016, International journal of vascular medicine.

[62]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[63]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[64]  N. Yanaihara,et al.  Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy , 2015, The journal of obstetrics and gynaecology research.

[65]  P. Daniels,et al.  Prevention of venous thromboembolism in patients undergoing bariatric surgery , 2015, Vascular health and risk management.

[66]  B. Dörken,et al.  Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  F. Germini,et al.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. , 2015, Chest.

[68]  Lara A. Kahale,et al.  Anticoagulation for people with cancer and central venous catheters. , 2014, The Cochrane database of systematic reviews.

[69]  Lara A. Kahale,et al.  Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2014, The Cochrane database of systematic reviews.

[70]  R. Yusen,et al.  Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. , 2014, Journal of the American College of Cardiology.

[71]  S. Goldhaber,et al.  Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.

[72]  J. Connors,et al.  New oral anticoagulants and the cancer patient. , 2014, The oncologist.

[73]  M. Di Nisio,et al.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2014, The Cochrane database of systematic reviews.

[74]  M. Menon,et al.  Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. , 2014, JAMA surgery.

[75]  G. Lyman,et al.  Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. , 2013, The oncologist.

[76]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[77]  H. Riess,et al.  [Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]. , 2013, Deutsche medizinische Wochenschrift.

[78]  I. Pabinger,et al.  Biomarkers for prediction of venous thromboembolism in cancer. , 2013, Blood.

[79]  N. Mackman,et al.  Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. , 2013, Blood.

[80]  S. Braekkan,et al.  Epidemiology of cancer-associated venous thrombosis. , 2013, Blood.

[81]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[82]  M. Prins,et al.  International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[83]  A. Khorana,et al.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[84]  D. Dunkler,et al.  Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  A. Maraveyas,et al.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. , 2012, European journal of cancer.

[86]  S. Barni,et al.  A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score , 2012, Internal and Emergency Medicine.

[87]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[88]  D. Cook,et al.  Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. , 2011, The Cochrane database of systematic reviews.

[89]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[90]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[91]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[92]  L. Jørgensen,et al.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. , 2009, The Cochrane database of systematic reviews.

[93]  Elie A Akl,et al.  Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. , 2008, Archives of internal medicine.

[94]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[95]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[96]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[97]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[98]  S. Laporte,et al.  Meta‐analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery , 2001, The British journal of surgery.

[99]  A A Rimm,et al.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.